Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

186 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients.
Haanen JB, Baars A, Gomez R, Weder P, Smits M, de Gruijl TD, von Blomberg BM, Bloemena E, Scheper RJ, van Ham SM, Pinedo HM, van den Eertwegh AJ. Haanen JB, et al. Among authors: baars a. Cancer Immunol Immunother. 2006 Apr;55(4):451-8. doi: 10.1007/s00262-005-0018-5. Epub 2005 Jul 21. Cancer Immunol Immunother. 2006. PMID: 16034562 Free PMC article. Clinical Trial.
Autologous tumor cell vaccination combined with systemic CpG-B and IFN-α promotes immune activation and induces clinical responses in patients with metastatic renal cell carcinoma: a phase II trial.
Koster BD, Santegoets SJAM, Harting J, Baars A, van Ham SM, Scheper RJ, Hooijberg E, de Gruijl TD, van den Eertwegh AJM. Koster BD, et al. Among authors: baars a. Cancer Immunol Immunother. 2019 Jun;68(6):1025-1035. doi: 10.1007/s00262-019-02320-0. Epub 2019 Mar 9. Cancer Immunol Immunother. 2019. PMID: 30852622 Free PMC article. Clinical Trial.
Local Adjuvant Treatment with Low-Dose CpG-B Offers Durable Protection against Disease Recurrence in Clinical Stage I-II Melanoma: Data from Two Randomized Phase II Trials.
Koster BD, van den Hout MFCM, Sluijter BJR, Molenkamp BG, Vuylsteke RJCLM, Baars A, van Leeuwen PAM, Scheper RJ, Petrousjka van den Tol M, van den Eertwegh AJM, de Gruijl TD. Koster BD, et al. Among authors: baars a. Clin Cancer Res. 2017 Oct 1;23(19):5679-5686. doi: 10.1158/1078-0432.CCR-17-0944. Clin Cancer Res. 2017. PMID: 28972083 Clinical Trial.
Correction to: Autologous tumor cell vaccination combined with systemic CpG-B and IFN-α promotes immune activation and induces clinical responses in patients with metastatic renal cell carcinoma: a phase II trial.
Koster BD, Santegoets SJAM, Harting J, Baars A, van Ham SM, Scheper RJ, Hooijberg E, de Gruijl TD, van den Eertwegh AJM. Koster BD, et al. Among authors: baars a. Cancer Immunol Immunother. 2019 Jun;68(6):1037. doi: 10.1007/s00262-019-02328-6. Cancer Immunol Immunother. 2019. PMID: 30919028 Free PMC article.
186 results